Invention of a New Non-Surgical Treatment for Bowel Cancer

Researchers in the UK have announced that they have successfully developed a new chemoradiotherapy treatment for bowel cancer that could spare patients from undergoing major surgery, marking a significant advance in the management of one of the most common cancers in the country. The new treatment relies on an innovative approach that precisely targets cancer cells while preserving healthy tissue, thereby reducing complications and accelerating recovery.

A major international clinical trial revealed that approximately 80 percent of patients with early-stage rectal cancer were able to avoid radical surgery involving complete removal of the rectum, after receiving the new chemoradiotherapy regimen combined with local surgical intervention when necessary. The results, published in the prestigious journal *The Lancet Oncology*, suggest the potential for a paradigm shift in treating this type of cancer, which sees around 4,100 new early-stage cases diagnosed annually in the UK alone.

These findings bring an end to decades of suffering, during which patients were forced to accept the loss of their rectum—along with resulting bowel dysfunction, urinary problems, and a permanent stoma bag—as the “price” of cancer treatment. However, Professor Simon Bach, lead researcher on the trial and professor of colorectal surgery at University College London, emphasized that these results indicate “that price no longer needs to be paid by many.”

The trial, named “STAR-TREC,” included more than 500 patients from five countries, including England, who were divided into three groups:

• Group 1: Received five weeks of chemoradiotherapy, with surgery performed to preserve the rectum if the treatment alone was insufficient to shrink the tumor.

• Group 2: Received only five days of radiotherapy, with the same surgical approach when necessary.

After one year of follow-up, patients who received five weeks of chemoradiotherapy were less likely to require radical surgery compared to those who received only five days of radiotherapy. Researchers are now continuing to monitor patients over the next three years to determine whether cancer is more likely to recur in the absence of radical surgery, and whether there are differences in survival rates.

Michelle Mitchell, chief executive of Cancer Research UK, which funded the trial in partnership with Stand Up To Cancer, praised the findings as “a breakthrough that could change the lives of thousands of people.” She noted that cancer screening has helped detect more cases of rectal cancer at an early stage, when survival chances are higher, but that this has not lessened the burden of treatment. She added: “It is striking that this may finally be about to change with this new treatment option, which has the potential to transform the lives of those diagnosed with this cancer and their families.”

For his part, Professor Peter Johnson, National Clinical Director for Cancer at the UK’s National Health Service (NHS), welcomed the results, describing them as “important in paving the way to avoid radical surgery for more people in the future.” He pointed out that the NHS is constantly striving to improve cancer treatment, and that many patients already benefit from receiving radiotherapy before surgery.

This development is the fruit of collaborative research between University College London, the University of Birmingham, and the University of Leeds, with the team hoping that this therapeutic approach will become the new standard of care as soon as possible. However, Professor Basha emphasized that “the next step is to ensure the durability of these results over the longer term, and then to guarantee that this approach is available to every patient who can benefit from it.”

This trial represents a significant turning point in the treatment of rectal cancer, offering patients hope of avoiding the devastating side effects of radical surgery without compromising cure rates. As patients continue to be followed over the next three years, the medical and scientific communities await the final results, which could shape a new era in the management of this malignant disease.